Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| United States Department of Defense | FED |
Not provided
Not provided
Not provided
Not provided
The researchers want to find out if an electronic application called MS CATCH can enhance patients' and doctors' experiences during and in between clinical visits. MS CATCH is a smartphone-based tool which allows patients to enter their mood related symptoms at regular intervals, which is then available to their Neurologist in their electronic medical record. The neurologist is also able to view additional information from their medical record, and receives alerts for changes reported by the patient that raise concern for the patient's mental health.
MS-CATCH (Care technology to Ascertain, Treat, and engage the Community to Heal depression in patients with Multiple Sclerosis) is a behaviorally informed, digital health, closed-loop-intervention that brings longitudinal mood reporting into the point of care. It consists of a simple tool used by the patient to improve mood reporting. This then triggers real-time alerts delivered to the clinician, who can access a comprehensive dashboard featuring risk factors and interventions to be considered, as well as resources local to the patient. This dashboard launches straight from the patient's electronic health record (EHR). MS-CATCH was designed using extensive human-centered design in all phases of development, and HIPAA compliant REDCap for electronic data capture. While the tool requires institutional approvals to launch within the UCSF EHR, the design elements could be readily repurposed using these technologies to support other institutions' requirements. Each individual care component and visualization was then developed and refined using extensive stakeholder engagement and an eye to the COM-B (Capability, Opportunity, and Motivation to change Behavior) principles of behavioral change, in order to promote behaviors likely to improve depression reporting, screening, comprehensive treatment and follow through.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1: 12 month MS CATCH tool intervention | Experimental | Participants in arm 1 will receive 12 months of use of the MS CATCH tool. This will include in-visit interventions and monthly questionnaires. |
|
| Arm 2: 6 month "usual care", 6 month MS CATCH tool intervention | Other | Participants in arm 2 will receive 6 months "usual care" followed by 6 months of MS CATCH tool intervention. These first 6 months will be used to assess the definition of "usual care". |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MS CATCH | Behavioral | Participants will respond to a set of surveys every month to increase communication on mood with their clinician. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mood Screening - Primary | Clinician screening of depression as documented in the electronic health record (EHR) | 0-6 months, 0-12 months |
| Mood Reporting - Secondary | The percentage of patients who self-report mood at each clinical visit | 6 months, Baseline, 12 months |
| Comprehensive Mood Evaluation - Secondary | The percentage of depression risk factors evaluated at each clinical visit | 0-6 months, 0-12 months |
| Treatment recommendations - Secondary | The percentage of visits in which applicable care was recommended; number of preventative care recommendations | 0-6 months, 0-12 months |
| Treatment recommendation follow-through - Secondary | The number/percent of preventative care recommendations followed through by next visit | 0-6 months, 0-12 months |
| Adoption (uptake) - Primary | The percentage of patients using the tool during the first month of the study | Initial month |
| Adoption (uptake) - Secondary | The percentage of patient-clinician dyads who use the in-clinic dashboard at first visit | Baseline, 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Mood scores - Primary | Hospital Anxiety Depression Scale (HADS) will be measured at baseline, 3, 6, 9, and 12 months, scale: 0-21 range for depressive scale, and 0-21 range for anxiety scale, with higher score meaning more depressive or anxious symptoms | Baseline, 3, 6, 9, and 12 months |
| Mood scores - Exploratory |
| Measure | Description | Time Frame |
|---|---|---|
| Trial retention - Exploratory | Trial retention | 12 months |
| Self-Efficacy - Exploratory | Changes in patient reported self efficacy at managing a chronic disease, reported using the "Self-efficacy for Managing a Chronic Disease 6-item Scale" (Lorig) Questionnaire. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Riley Bove, MD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Weill Institute for Neurosciences, University of California, San Francisco | San Francisco | California | 94158 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38488827 | Derived | Henderson K, Reihm J, Koshal K, Wijangco J, Sara N, Miller N, Doyle M, Mallory A, Sheridan J, Guo CY, Oommen L, Rankin KP, Sanders S, Feinstein A, Mangurian C, Bove R. A Closed-Loop Digital Health Tool to Improve Depression Care in Multiple Sclerosis: Iterative Design and Cross-Sectional Pilot Randomized Controlled Trial and its Impact on Depression Care. JMIR Form Res. 2024 Mar 15;8:e52809. doi: 10.2196/52809. | |
| 38401894 |
Not provided
Not provided
The deidentified dataset will be shared with qualified collaborators upon request, provision of CITI and other certifications, and data sharing agreement. We will share the results, once the data are complete and analyzed, with the scientific community and patient/clinician participants through abstracts, presentations and manuscripts.
6 months post trial
Qualified collaborators upon request, provision of CITI and other certifications, and data sharing agreement
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D003863 | Depression |
| D003244 | Consciousness Disorders |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Both arm 1 and arm 2 groups of participants will receive at least 6 months of MS CATCH tool intervention, with arm 1 receiving 12 months of intervention
Not provided
Not provided
The statistician will be blinded to what arm participants are a part of.
Mini-International Neuropsychiatric Interview (MINI) assessment |
| 12 months |
| Mood scores - Exploratory | Changes in Patient Health Questionnaire - 9 (PHQ-9), scale: 0-27, higher indicates more severe depressive symptoms | 0-12 months, 0-6 months, 6-12 months |
| Other self-reported outcome - Modified Fatigue Impact Scale - Exploratory | Evaluating possible contributors to mood: fatigue (MFIS), scale: 0-84, higher score indicates more impact | 0-12 months, 0-6 months, 6-12 months |
| Other self-reported outcome - Pittsburgh Sleep Quality Index - Exploratory | Evaluating possible contributors to mood: sleep (PSQI), scale: 0-21, higher scores indicates worse sleep quality | 0-12 months, 0-6 months, 6-12 months |
| Other self-reported outcome - Oxford-Participation and Activities Questionnaire - Exploratory | Evaluating possible contributors to mood: engagement (Ox-PAQ), scale: 0-100, higher score indicates more problems with activity and participation | 0-12 months, 0-6 months, 6-12 months |
| Other self-reported outcome - Impact on Participation and Autonomy - Exploratory | Evaluating possible contributors to mood: participation (IPA), scale: 0-128, with higher score indicating more impact on a person's autonomy and participation | 0-12 months, 0-6 months, 6-12 months |
| Engagment (Sustained use) - Secondary | The percentage of patients who continue to use the patient-facing tool at least quarterly | Every 3 months |
| Engagement (Sustained use) - Secondary | The percentage of patient-clinician dyads in Arm 1 (early start) who continued to use the tool at the 12 month visit | 12 months |
| Engagement (Sustained use) - Exploratory | Length of each session | Baseline, 6 month, 12 month |
| Engagement (Sustained use) - Exploratoy | Qualitative feedback in exit interviews | 12 month |
| Engagement (Sustained use) - Exploratory | Net promoter score (NPS) | 12 month |
| Adherence - Secondary | The percentage of depression-reporting prompts responded to per participant on their patient-facing tool; the percentage participants responding to >75% depression prompts | 12 months |
| Baseline-12 months |
| Derived |
| Henderson K, Reihm J, Koshal K, Wijangco J, Miller N, Sara N, Doyle M, Mallory A, Sheridan J, Guo CY, Oommen L, Feinstein A, Mangurian C, Lazar A, Bove R. Pragmatic phase II clinical trial to improve depression care in a real-world diverse MS cohort from an academic MS centre in Northern California: MS CATCH study protocol. BMJ Open. 2024 Feb 24;14(2):e077432. doi: 10.1136/bmjopen-2023-077432. |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |